New Lung-Sparing surgery aims to remove deep tumors while preserving breathing
NCT ID NCT07564557
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new surgical technique called septum-guided segmentectomy for people with small, early-stage lung cancer located deep in the lung. The goal is to remove the cancer completely while saving as much healthy lung tissue as possible, which may help preserve breathing function. About 89 participants will have the surgery and be followed for 3 years to check for cancer return and recovery.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 89 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Apr 2026
- Expected to finish
-
Apr 2031
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 80 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Age 18-80 years * Clinical stage IA (cT1a-bN0M0) * tumor diameter ≤ 2 cm * Pathological feature: Solid-dominant lesion (CTR \> 0.5) * Tumor location: Deep-seated within the lung parenchyma (inner 2/3), defined as the tumor center being located in the inner 2/3 region of the lung field on axial, coronal, and sagittal CT views * ECOG Performance Status: 0-1 * Pulmonary function: FEV1 ≥ 60% predicted and DLCO SB ≥ 60% predicted * Participants must be willing and able to provide written informed consent Exclusion Criteria: * Multiple pulmonary nodules or evidence of distant metastasis * Intraoperative confirmation of lymph node metastasis (N1/N2) or pleural dissemination * History of previous ipsilateral lung surgery * History of other malignant tumors within the past 5 years * Presence of severe cardiovascular or cerebrovascular diseases that preclude surgical tolerance * Pregnancy or breastfeeding
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Deep-seated lung nodules are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Shanghai Chest Hospital
RECRUITINGShanghai, Shanghai Municipality, 200030, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Surgeons could freeze lung tumors from miles away using 5G robots
- Two-Drug combo targets stubborn KRAS lung cancer
- Smaller chest drain may speed recovery after lung cancer surgery
- Gut bacteria may hold clues to why some cancer treatments work better
- Breath-Tracking sensor aims to sharpen lung cancer scans
- Can PET scan signals predict who beats lung cancer with immunotherapy?